These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 25213800)

  • 1. Cost-utility analysis of glucagon-like Peptide-1 agonists compared with dipeptidyl peptidase-4 inhibitors or neutral protamine hagedorn Basal insulin as add-on to metformin in type 2 diabetes in sweden.
    Kiadaliri AA; Gerdtham UG; Eliasson B; Carlsson KS
    Diabetes Ther; 2014 Dec; 5(2):591-607. PubMed ID: 25213800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective.
    Charokopou M; McEwan P; Lister S; Callan L; Bergenheim K; Tolley K; Postema R; Townsend R; Roudaut M
    BMC Health Serv Res; 2015 Nov; 15():496. PubMed ID: 26541516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-utility analysis of second-line anti-diabetic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin.
    Chien CL; Chen YC; Malone DC; Peng YL; Ko Y
    Curr Med Res Opin; 2020 Oct; 36(10):1619-1626. PubMed ID: 32851879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of insulin detemir compared with NPH insulin in people with type 2 diabetes in Denmark, Finland, Norway, and Sweden.
    Ridderstråle M; Jensen MM; Gjesing RP; Niskanen L
    J Med Econ; 2013; 16(4):468-78. PubMed ID: 23384160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness Analysis of Sensor-Augmented Insulin Pump Therapy with Automated Insulin Suspension Versus Standard Insulin Pump Therapy in Patients with Type 1 Diabetes in Sweden.
    Jendle J; Smith-Palmer J; Delbaere A; de Portu S; Papo N; Valentine W; Roze S
    Diabetes Ther; 2017 Oct; 8(5):1015-1030. PubMed ID: 28871565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of once-daily oral semaglutide versus placebo and subcutaneous glucagon-like peptide-1 receptor agonists added to insulin in patients with type 2 diabetes in China.
    Feng Z; Tong WK; Zhang X; Tang Z
    Front Pharmacol; 2023; 14():1226778. PubMed ID: 37621313
    [No Abstract]   [Full Text] [Related]  

  • 7. Cost-Effectiveness Analysis of Insulin Detemir Compared to Neutral Protamine Hagedorn (NPH) in Patients with Type 1 and Type 2 Diabetes Mellitus in Spain.
    Morales C; de Luis D; de Arellano AR; Ferrario MG; Lizán L
    Diabetes Ther; 2015 Dec; 6(4):593-610. PubMed ID: 26589521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF; Mannucci E; Ahrén B
    Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece.
    Tzanetakos C; Tentolouris N; Kourlaba G; Maniadakis N
    Clin Drug Investig; 2016 Aug; 36(8):649-59. PubMed ID: 27221806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-Effectiveness Analysis of Exenatide versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus.
    Capel M; Ciudin A; Mareque M; Rodríguez-Rincón RM; Simón S; Oyagüez I
    Pharmacoecon Open; 2020 Jun; 4(2):277-286. PubMed ID: 31338828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Cost-Effectiveness of Insulin Glargine Versus Neutral Protamine Hagedorn Insulin for Type 2 Diabetes in Thailand.
    Permsuwan U; Chaiyakunapruk N; Dilokthornsakul P; Thavorn K; Saokaew S
    Appl Health Econ Health Policy; 2016 Jun; 14(3):281-92. PubMed ID: 26961276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Cost-Effectiveness of Lorlatinib Versus Chemotherapy as a Second- or Third-Line Treatment in Anaplastic Lymphoma Kinase (ALK)-Positive Non-small-cell Lung Cancer in Sweden.
    Nilsson FOL; Asanin ST; Masters ET; Iadeluca L; Almond C; Cooper M; Smith S
    Pharmacoeconomics; 2021 Aug; 39(8):941-952. PubMed ID: 34080140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of add-on treatments to metformin in a Swedish setting: liraglutide vs sulphonylurea or sitagplitin.
    Steen Carlsson K; Persson U
    J Med Econ; 2014 Sep; 17(9):658-69. PubMed ID: 24950434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Indirect comparison of lixisenatide versus neutral protamine Hagedorn insulin as add-on to metformin and sulphonylurea in patients with type 2 diabetes mellitus.
    Fournier M; Germe M; Theobald K; Scholz GH; Lehmacher W
    Ger Med Sci; 2014; 12():Doc14. PubMed ID: 25332702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis.
    Tunis SL; Minshall ME; Conner C; McCormick JI; Kapor J; Yale JF; Groleau D
    Curr Med Res Opin; 2009 May; 25(5):1273-84. PubMed ID: 19366302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Cost Effectiveness of Oral Semaglutide Versus Empagliflozin and Sitagliptin for the Treatment of Type 2 Diabetes in the Swedish Setting.
    Eliasson B; Ericsson Å; Fridhammar A; Nilsson A; Persson S; Chubb B
    Pharmacoecon Open; 2022 May; 6(3):343-354. PubMed ID: 35064550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness Analysis of the MiniMed 670G Hybrid Closed-Loop System Versus Continuous Subcutaneous Insulin Infusion for Treatment of Type 1 Diabetes.
    Jendle J; Pöhlmann J; de Portu S; Smith-Palmer J; Roze S
    Diabetes Technol Ther; 2019 Mar; 21(3):110-118. PubMed ID: 30785311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term cost-effectiveness of insulin detemir versus NPH insulin in type 2 diabetes in Sweden.
    Smith-Palmer J; Fajardo-Montañana C; Pollock RF; Ericsson A; Valentine WJ
    J Med Econ; 2012; 15(5):977-86. PubMed ID: 22563742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Cost-Effectiveness of Subcutaneous Semaglutide Versus Empagliflozin in Type 2 Diabetes Uncontrolled on Metformin Alone in Denmark.
    Ehlers LH; Lamotte M; Ramos MC; Sandgaard S; Holmgaard P; Kristensen MM; Ejskjaer N
    Diabetes Ther; 2022 Mar; 13(3):489-503. PubMed ID: 35187628
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.